JP2021530444A5 - - Google Patents
Info
- Publication number
- JP2021530444A5 JP2021530444A5 JP2020571522A JP2020571522A JP2021530444A5 JP 2021530444 A5 JP2021530444 A5 JP 2021530444A5 JP 2020571522 A JP2020571522 A JP 2020571522A JP 2020571522 A JP2020571522 A JP 2020571522A JP 2021530444 A5 JP2021530444 A5 JP 2021530444A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- specifically binds
- group
- pharmaceutical composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015837A JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691486P | 2018-06-28 | 2018-06-28 | |
| US62/691,486 | 2018-06-28 | ||
| US201862697526P | 2018-07-13 | 2018-07-13 | |
| US62/697,526 | 2018-07-13 | ||
| PCT/US2019/039620 WO2020006312A1 (en) | 2018-06-28 | 2019-06-27 | Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Division JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530444A JP2021530444A (ja) | 2021-11-11 |
| JP2021530444A5 true JP2021530444A5 (https=) | 2022-07-04 |
Family
ID=68987577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571522A Pending JP2021530444A (ja) | 2018-06-28 | 2019-06-27 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12466869B2 (https=) |
| EP (1) | EP3813863A4 (https=) |
| JP (2) | JP2021530444A (https=) |
| CN (1) | CN112399852A (https=) |
| AU (1) | AU2019291882A1 (https=) |
| WO (1) | WO2020006312A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021076197A1 (en) | 2019-10-15 | 2021-04-22 | Diverse Biotech, Inc. | Conjugate molecules |
| US20220354815A1 (en) * | 2019-11-19 | 2022-11-10 | Oklahoma Medical Research Foundation | Okn-007 as a therapeutic agent |
| WO2022099065A1 (en) * | 2020-11-05 | 2022-05-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Conditional control of universal car t cells through stimulus-reactive adaptors |
| JP2023552810A (ja) * | 2020-12-08 | 2023-12-19 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 抗ｅｇｆｒキメラ抗原受容体 |
| US11660348B1 (en) | 2022-02-01 | 2023-05-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| US11883499B2 (en) | 2022-02-01 | 2024-01-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| WO2025085511A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Washington | Systems and methods for polymer-mediated activation of engineered cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP2010207133A (ja) * | 2009-03-10 | 2010-09-24 | Sony Corp | 細胞分離方法 |
| EP3323830B1 (en) * | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| US9233125B2 (en) | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CN105814083A (zh) * | 2013-10-15 | 2016-07-27 | 加州生物医学研究所 | 嵌合抗原受体t细胞开关和其用途 |
| WO2015168656A2 (en) * | 2014-05-02 | 2015-11-05 | Adheren Incorporated | Biological complexes and methods for using same |
| SI3597742T1 (sl) | 2014-10-09 | 2022-11-30 | Yamaguchi University | CAR ekspresijski vektor in T celice, ki izražajo CAR |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| WO2016168769A1 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CN105504042A (zh) | 2016-02-04 | 2016-04-20 | 北京艺妙神州医疗科技有限公司 | 检测car-t细胞的捕获探针、该细胞含量的检测方法及应用 |
| JP2019508036A (ja) * | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| US20170274095A1 (en) | 2016-03-23 | 2017-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| CA3053534A1 (en) | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US20200306376A1 (en) * | 2017-04-25 | 2020-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for targeted tumor immunotherapy |
| CN108490174B (zh) | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
| CN108660113A (zh) | 2018-05-21 | 2018-10-16 | 杭州启澜生物医学技术有限公司 | 一种制备改良型car-t细胞的方法 |
-
2019
- 2019-06-27 JP JP2020571522A patent/JP2021530444A/ja active Pending
- 2019-06-27 CN CN201980043041.XA patent/CN112399852A/zh active Pending
- 2019-06-27 EP EP19825236.3A patent/EP3813863A4/en active Pending
- 2019-06-27 US US17/254,472 patent/US12466869B2/en active Active
- 2019-06-27 WO PCT/US2019/039620 patent/WO2020006312A1/en not_active Ceased
- 2019-06-27 AU AU2019291882A patent/AU2019291882A1/en not_active Abandoned
-
2025
- 2025-02-03 JP JP2025015837A patent/JP2025072462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530444A5 (https=) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP2020505433A5 (https=) | ||
| JP2008503476A5 (https=) | ||
| JP2018524347A5 (https=) | ||
| JP2022523740A5 (https=) | ||
| JP2019506403A5 (https=) | ||
| JP2008530142A5 (https=) | ||
| JP2012509889A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2013520442A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2014510729A5 (https=) | ||
| WO2019089641A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use | |
| JP2026503515A (ja) | 非ホジキンリンパ腫治療用医薬組成物及びその使用 | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2022535609A5 (https=) | ||
| Lehnert et al. | Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer | |
| JP2015518053A5 (https=) | ||
| JP2023540206A5 (https=) | ||
| CN110831604B (zh) | 用于肿瘤治疗或预防的药物组合物、方法及其用途 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| JP2021521219A (ja) | Ｂｅｔ阻害剤およびプロテアソーム阻害剤を用いる併用療法 |